For the year ending 2025-12-31, SUPN made $718,952K in revenue. -$38,550K in net income. Net profit margin of -5.36%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenues | 718,952 | 661,817 | ||
| Cost of revenues | 74,562 | 77,906 | ||
| Research and development | 106,235 | 108,796 | ||
| Selling, general and administrative | 485,563 | 321,582 | ||
| Amortization of intangible assets | 89,456 | 77,977 | ||
| Intangible asset impairment charges | 0 | - | ||
| Contingent consideration loss (gain) | 25,419 | -6,110 | ||
| Total costs and expenses | 781,235 | 580,151 | ||
| Operating earnings (loss) | -62,283 | 81,666 | ||
| Interest and other income, net | 13,253 | 16,204 | ||
| Interest expense | 0 | - | ||
| Total other income (expense), net | 13,253 | 16,204 | ||
| Earnings (loss) before income taxes | -49,030 | 97,870 | ||
| Income tax expense (benefit) | -10,480 | 24,005 | ||
| Net earnings (loss) | -38,550 | 73,865 | ||
| Basic EPS | -0.68 | 1.34 | ||
| Diluted EPS | -0.68 | 1.32 | ||
| Basic Average Shares | 56,451,136 | 55,100,063 | ||
| Diluted Average Shares | 56,451,136 | 55,958,537 | ||
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
SUPERNUS PHARMACEUTICALS, INC. (SUPN)